A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Clinical trial NCT07047118 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07047118
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-03
- Primary completion
- 2027-07-16
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.